Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -35

Oppenheimer cuts target for Boston Scientific stock from USD 85.00 to USD 65.00

Analyst downgrade Operational disruption AI-generated analysis

πŸ“‰ Oppenheimer cut its target for Boston Scientific stock from USD 85.00 to USD 65.00 due to a cybersecurity incident disrupting operations.

πŸ”’ A recent cyberattack prevented Boston Scientific from meeting its previously issued third-quarter and full-year 2026 sales and adjusted profit forecasts.

πŸ’° Q2 2026 revenue reached USD 5.44 billion, up 7.50% year over year, exceeding the USD 5.38 billion analyst expectation.

πŸ“Š Adjusted earnings per share hit USD 0.86, beating the USD 0.83 consensus despite operational disruptions.

πŸ—“οΈ The company will provide an updated outlook with third-quarter results on October 28, 2026.

🏒 Boston Scientific has a market capitalization of USD 63.3 billion as of October 5, 2026.

πŸ“ˆ Stock traded at EUR 38.00 on October 5, 2026, up 0.34% versus the prior close.

πŸ›‘οΈ The cybersecurity incident disrupted manufacturing, order processing, and shipments for Boston Scientific.

Bullish Signals
  • Boston Scientific reported Q2 2026 revenue of USD 5.44 billion, representing a 7.50% year-over-year increase that exceeded analyst expectations.
  • The company achieved adjusted earnings per share of USD 0.86 in the second quarter, surpassing the USD 0.83 consensus estimate.
  • Despite operational disruptions from a cyberattack, Boston Scientific demonstrated underlying business strength with revenue and earnings beats.
Risk Factors
  • Oppenheimer downgraded its price target for Boston Scientific stock from USD 85.00 to USD 65.00 following a cybersecurity incident.
  • A recent cyberattack disrupted Boston Scientific's manufacturing, order processing, and shipments, impacting operational efficiency.
  • The security breach is likely to prevent Boston Scientific from meeting its previously issued third-quarter and full-year 2026 sales and adjusted profit forecasts.
Full Analysis
Oppenheimer has downgraded its price target for Boston Scientific stock from USD 85.00 to USD 65.00 following a significant cybersecurity incident that disrupted the company's manufacturing, order processing, and shipment operations. This negative analyst action reflects concerns regarding the impact of the breach on near-term execution and the ability to meet previously issued financial forecasts for the third quarter and full year of 2026. Despite the cyberattack, Boston Scientific reported strong second-quarter performance with revenue reaching USD 5.44 billion, a 7.50% increase year over year that exceeded analyst expectations of USD 5.38 billion. Adjusted earnings per share also beat consensus at USD 0.86 versus the expected USD 0.83, demonstrating underlying business resilience even as the company faces operational headwinds from the security breach. The company plans to release an updated financial outlook alongside its third-quarter results on October 28, 2026, which will serve as a critical checkpoint for investors assessing the timeline of operational recovery and revised guidance. As of mid-October 2026, Boston Scientific maintains a market capitalization of USD 63.3 billion while trading around EUR 38.00, with the stock price reflecting mixed signals between recent earnings beats and the looming risks from the cyber incident.